Menkes Disease Drug Treatment Market Poised To Grow At A Robust Pace Due To Increasing Prevalence Of Menkes Disease

 

Menkes disease, a rare X-linked genetic disorder affecting copper metabolism caused by mutations in ATP7A gene, leads to impaired absorption and transport of dietary copper in the body. Patients suffering from Menkes disease exhibit neurodegenerative features and connective tissue abnormalities. Drug treatment options such as copper histidine, copper chloride, and zinc acetate are used to manage the symptoms of Menkes disease.

The Menkes Disease Market is estimated to be valued at US$ 165.1 million in 2024 and is expected to exhibit a CAGR of 6.6% over the forecast period of 2024-2031.

The need for drugs to manage copper deficiency and improve health outcomes in patients suffering from Menkes disease is driving market growth.

Key Takeaways

Key players operating in the Menkes disease drug treatment market are Fortress Biotech, Inc., Teva Pharmaceutical Industries Ltd.,Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health Companies Inc. Fortress Biotech is advancing a gene therapy candidate FORT-101 to treat Menkes disease.

Enhanced patient awareness and supportive initiatives by foundations like MDEBRA are creating opportunities for wider adoption of drug treatments. The increasing R&D for next-generation therapies like gene therapy by key players is expected to boost the global market over the forecast period.

Driven by the unmet need, major players are partnering with smaller biotechs to expand the treatment landscape to regions like Asia Pacific and Latin America. Investments in early diagnosis through newborn screening programs will aid global expansion efforts in the Menkes disease market.

Market Drivers

- Increasing prevalence of Menkes disease globally - As per estimates, Menkes disease affects 1 in 34,000-39,000 newborn males.

- Growing diagnosis rate through newborn screening programs tailored to detect Menkes disease

Market Restraints

- High cost of drugs hampers access in low and middle-income countries

- Limited treatment options available presently for severe Menkes disease phenotypes.

Segment Analysis

The Menkes Disease Market is segmented based on treatment type, route of administration and distribution channel. By treatment type, the copper histadine segment dominates the market and accounts for the largest revenue share. Copper histadine treats Menkes disease by facilitating copper absorption in the body. It is extensively prescribed by physicians owing to its effectiveness in managing signs and symptoms of the disease.

By route of administration, the oral segment commands the highest market share. Oral route of administering copper histadine is convenient and non-invasive. This drives its demand over other administration routes.

Lastly, hospital pharmacies hold the dominant position based on distribution channel. Majority of copper histadine prescriptions are fulfilled through hospital pharmacies as patients requiring treatment for Menkes disease prefer obtaining drugs from these facilities for ensuring effective management.

Global Analysis

The North America region accounts for the highest share in the Menkes Disease Market. This is attributed to increasing awareness about Menkes disease, high diagnosis rates backed by advanced healthcare infrastructure and widespread availability of treatment drugs across the region. Additionally, presence of leading market players is boosting market growth in North America. Europe is the second largest regional market fueled by rising healthcare expenditure and government support for rare disease treatment. The Asia Pacific region exhibits the highest growth rate over the forecast period driven by improving patient access to diagnosis and drugs in highly populated nations such as China and India.

Get more insights on this topic: https://www.marketwebjournal.com/menkes-disease-market-is-estimated-to-witness-high-growth-owing-to-rising-prevalence-of-rare-diseases/

 

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Menkes Disease Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Menkes Disease Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Menkes Disease Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Menkes Disease Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Menkes Disease Market vendors

FAQ’s

Q.1 What are the main factors influencing the Menkes Disease Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Menkes Disease Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Menkes Disease Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it